2552 Stock Overview
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China.
Hua Medicine (Shanghai) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$3.84|
|52 Week High||HK$5.38|
|52 Week Low||HK$2.40|
|1 Month Change||-1.54%|
|3 Month Change||6.67%|
|1 Year Change||-19.50%|
|3 Year Change||-44.99%|
|5 Year Change||n/a|
|Change since IPO||-53.62%|
Recent News & Updates
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|2552||HK Pharmaceuticals||HK Market|
Return vs Industry: 2552 exceeded the Hong Kong Pharmaceuticals industry which returned -43.3% over the past year.
Return vs Market: 2552 exceeded the Hong Kong Market which returned -23.3% over the past year.
|2552 Average Weekly Movement||9.5%|
|Pharmaceuticals Industry Average Movement||6.1%|
|Market Average Movement||7.0%|
|10% most volatile stocks in HK Market||13.8%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 2552 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 2552's weekly volatility (9%) has been stable over the past year.
About the Company
Hua Medicine (Shanghai) Ltd. operates as a clinical-stage drug development company that focuses on therapies for the treatment of diabetes in China. It develops Dorzagliatin or HMS5552, an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin that is in Phase I clinical trial for treatment of T2D. The company also offers Dorzagliatin in combination with Pioglitazone for NASH; in combination with GLP-1 for Alzheimer diseases; and in combination with late stage T2D and Type 1 Diabetes.
Hua Medicine (Shanghai) Fundamentals Summary
|2552 fundamental statistics|
Is 2552 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|2552 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.34|
|Net Profit Margin||-5,019.01%|
How did 2552 perform over the long term?See historical performance and comparison
Is 2552 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2552?
Other financial metrics that can be useful for relative valuation.
|What is 2552's n/a Ratio?|
Price to Book Ratio vs Peers
How does 2552's PB Ratio compare to its peers?
|2552 PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
1681 Consun Pharmaceutical Group
2877 China Shineway Pharmaceutical Group
6622 Zhaoke Ophthalmology
6600 SciClone Pharmaceuticals (Holdings)
2552 Hua Medicine (Shanghai)
Price-To-Book vs Peers: 2552 is expensive based on its Price-To-Book Ratio (7x) compared to the peer average (1.2x).
Price to Earnings Ratio vs Industry
How does 2552's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?
Price-To-Book vs Industry: 2552 is expensive based on its Price-To-Book Ratio (7x) compared to the Hong Kong Pharmaceuticals industry average (1x)
Price to Book Ratio vs Fair Ratio
What is 2552's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||7x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate 2552's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 2552 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 2552 (HK$3.84) is trading below our estimate of fair value (HK$44.02)
Significantly Below Fair Value: 2552 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 2552's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Hua Medicine (Shanghai) forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2552 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: 2552 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 2552 is expected to become profitable in the next 3 years.
Revenue vs Market: 2552's revenue (64.2% per year) is forecast to grow faster than the Hong Kong market (10.3% per year).
High Growth Revenue: 2552's revenue (64.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2552's Return on Equity is forecast to be very high in 3 years time (51.6%).
Discover growth companies
How has Hua Medicine (Shanghai) performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 2552 is currently unprofitable.
Growing Profit Margin: 2552 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 2552 is unprofitable, but has reduced losses over the past 5 years at a rate of 25% per year.
Accelerating Growth: Unable to compare 2552's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2552 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).
Return on Equity
High ROE: 2552 has a negative Return on Equity (-72.33%), as it is currently unprofitable.
Discover strong past performing companies
How is Hua Medicine (Shanghai)'s financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: 2552's short term assets (CN¥704.6M) exceed its short term liabilities (CN¥106.9M).
Long Term Liabilities: 2552's short term assets (CN¥704.6M) exceed its long term liabilities (CN¥346.3M).
Debt to Equity History and Analysis
Debt Level: 2552 is debt free.
Reducing Debt: 2552 currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 2552 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 2552 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Hua Medicine (Shanghai) current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 2552's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 2552's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 2552's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 2552's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 2552 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Li Chen (59 yo)
Dr. Li Chen, Ph.D. is the Co-Founder of Hua Medicine (Shanghai) Ltd. and serves as its Chief Scientific Officer and served as its President until May 19, 2016 and has been its Chief Executive Officer since...
CEO Compensation Analysis
Compensation vs Market: Li's total compensation ($USD3.57M) is above average for companies of similar size in the Hong Kong market ($USD393.76K).
Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.
Experienced Management: 2552's management team is considered experienced (3.2 years average tenure).
Experienced Board: 2552's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Hua Medicine (Shanghai) Ltd.'s employee growth, exchange listings and data sources
- Name: Hua Medicine (Shanghai) Ltd.
- Ticker: 2552
- Exchange: SEHK
- Founded: 2011
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$3.701b
- Shares outstanding: 963.73m
- Website: https://www.huamedicine.com
Number of Employees
- Hua Medicine (Shanghai) Ltd.
- Building A
- Room 2005
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.